Comparative risk of hypogammaglobulinemia across bispecific T-cell engagers: a class-level pharmacovigilance study
This pharmacovigilance study of FDA adverse event reports reveals that hypogammaglobulinemia is a target-dependent safety concern among bispecific T-cell engagers, with BCMA-directed agents exhibiting the strongest signal and highest risk of serious infections compared to other targets.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer immunotherapy has given doctors a powerful new way to fight blood cancers by turning the patient's own immune system against the disease. Among the most promising tools are drugs called bispecific T-cell engagers. These medicines act like a bridge, physically connecting a patient's immune T-cells to cancer cells, forcing the immune system to attack the tumor. While this approach has transformed treatment for many, it comes with a complex side effect profile. Because these drugs are so effective at wiping out cancer cells, they can also inadvertently deplete healthy immune cells, leaving the body vulnerable to infections. One specific consequence of this depletion is a condition where the blood lacks sufficient antibodies, the proteins that normally neutralize germs. This shortage, known as hypogammaglobulinemia, can persist long after treatment ends, creating a lingering risk of serious illness.
Researchers have long known that these drugs cause antibody shortages, but they did not know if the risk was the same for every type of drug in this family. Different versions of these medicines target different markers on cancer cells. Some aim at markers found on B-cells, while others target markers found on plasma cells, which are the factories that produce antibodies. A team of scientists set out to determine whether the risk of losing antibody protection varied depending on which target the drug was designed to hit. They wanted to know if some drugs were safer than others and how often this antibody loss led to actual infections in the real world.
To answer these questions, the researchers turned to a massive global database of medical reports called FAERS. This system collects spontaneous reports from doctors, patients, and manufacturers about adverse events linked to medications. The team analyzed over 11,000 reports involving eight different bispecific T-cell engager drugs approved by the US Food and Drug Administration. They looked specifically for mentions of low antibody levels and examined whether these cases were accompanied by reports of infections like pneumonia or viral reactivations. By comparing the frequency of these reports across the different drugs, they could identify which targets carried the highest risk.
The analysis revealed a clear and significant difference in risk depending on the drug's target. Drugs designed to attack a marker called BCMA, which is found on plasma cells, showed the strongest signal for causing low antibody levels. Two specific drugs in this group, teclistamab and elranatamab, were associated with a much higher rate of reported hypogammaglobulinemia compared to other drugs in the same class. In fact, the risk associated with the BCMA-targeting group was nearly three times higher than the risk associated with drugs that target CD20, a marker found on mature B-cells. This finding suggests that drugs which wipe out the antibody-producing factories directly cause a more profound and lasting drop in immune protection than those that simply remove the cells that eventually become factories.
The study also uncovered that not all drugs targeting the same marker behave the same way. Within the group of drugs that target CD20, there was a wide variation in risk. One drug, mosunetuzumab, showed a risk level similar to the high-risk BCMA drugs, while two other drugs in the same category, glofitamab and epcoritamab, showed no significant signal for low antibody levels at all. This indicates that even when drugs aim at the same biological target, their specific design and how they are administered can lead to very different safety outcomes. Another drug targeting a marker called GPRC5D showed a borderline signal, while a drug targeting a marker found in lung cancer, DLL3, had no reports of low antibody levels, likely because it is used in a different type of cancer where the immune system is not as deeply affected.
Beyond just counting the reports, the researchers looked at the timing of these events and the infections that followed. They found that for the high-risk BCMA drugs, the reports of low antibody levels tended to accumulate over time, suggesting that the immune system's ability to produce antibodies continues to decline the longer a patient is treated. In contrast, for the CD20 drugs, the reports appeared earlier, consistent with a rapid drop in antibody levels that happens soon after treatment begins. Most critically, the study found that nearly 40 percent of the patients who developed low antibody levels also reported a concurrent infection. The most common infections were pneumonia, a viral reactivation called cytomegalovirus, and upper respiratory infections. This high rate of infection underscores that the loss of antibodies is not just a laboratory number but a real-world danger that leaves patients susceptible to life-threatening illnesses.
The researchers concluded that low antibody levels are a class-wide concern for these immunotherapies, but the severity depends heavily on the specific drug and its target. The findings suggest that doctors should not treat all patients the same way. Patients receiving BCMA-targeting drugs, and specifically those receiving mosunetuzumab, may need more frequent monitoring of their antibody levels and a lower threshold for receiving antibody replacement therapy to prevent infections. The study emphasizes that while these drugs are powerful weapons against cancer, managing their long-term impact on the immune system requires a tailored approach based on the specific biology of the drug being used.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.